Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPsychiatry/Behavioral Healthsanfranciscohealthplan buprenorphine policy update…
    Ask Trek AI about this page
    CurrentsanfranciscohealthplanPolicy N/A

    Buprenorphine prescribing after DATA-Waiver removal

    Customize your policy alerts

    Sign up for all sanfranciscohealthplan policy alerts

    Know when sanfranciscohealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Explains DEA removal of the DATA-Waiver (X-Waiver) and the resulting change that standard DEA registration with Schedule III authority is sufficient for prescribing buprenorphine for opioid use disorder; affects practitioners who prescribe controlled substances and members/providers of San Francisco Health Plan.

    Policy Summary
    Payersanfranciscohealthplan
    PolicyBuprenorphine prescribing after DATA-Waiver removal
    Policy CodePolicy N/A
    Change TypeOperational — removal of DATA-WaiverDEA training added
    Effective DateJan 12, 2023
    Next Review DateN/A
    Key ActionEnsure prescriber has and maintains a current DEA registration that includes Schedule III authority before prescribing buprenorphine.
    SourceLink
    POLICY UPDATE CHANGES

    The DATA-Waiver (X-Waiver) registration numbers are no longer needed for any buprenorphine prescription.

    Any practitioner with a current DEA registration that includes Schedule III authority may now prescribe buprenorphine for OUD.

    New DEA training requirements (an eight-hour addiction identification and treatment training) will take effect for prescribers when applying for or renewing DEA registration on June 21, 2023.

    no limitPrescriber patient limit for OUD buprenorphine
    Schedule III

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required DEA authority
    8 hrsRequired training length (effective 6/21/2023)

    Coverage Criteria for Buprenorphine Prescribing

    Prescriber Authorization to Prescribe Buprenorphine

    Covered when ALL of the following are met

    Prescriber DEA registration: Prescriber has current DEA registration that includes Schedule III authority

    No separate DATA-Waiver/X-Waiver required

    The policy does not list any additional clinical exclusions for buprenorphine prescribing beyond standard DEA registration requirements. Specifically, there are no stated clinical conditions or member-level exclusions that would prohibit prescribing buprenorphine for opioid use disorder; coverage is tied to prescriber authorization rather than patient clinical exclusions.

    This document does not identify any circumstances or diagnoses as not medically necessary for buprenorphine treatment. No explicit "not medically necessary" conditions are specified; coverage considerations focus on prescriber DEA registration status rather than clinical exclusion criteria.

    Coding and Administrative Details

    No specific codes listedmixed
    No codes listed
    inv-05: Training hours required upon DEA registration application/renewal — 8 hours
    Required training length8 hours of addiction identification and treatment training upon DEA registration application or renewal (effective 6/21/2023)
    When requiredWhen a practitioner applies for or renews DEA registration to prescribe controlled substances
    ScopeApplies to all prescribers of controlled substances per DEA rule effective June 21, 2023

    Provider Actions, Documentation, and Risk

    Prior Authorization

    DATA‑Waiver/X‑Waiver no longer required for buprenorphine

    No DATA‑Waiver/X‑Waiver number is required; a standard DEA registration that includes Schedule III authority is sufficient for buprenorphine prescriptions.

    Note

    Prescriptive authority and patient limits

    Prescribers should be aware of DEA regulatory changes: any practitioner with a current DEA registration that includes Schedule III authority may prescribe buprenorphine for OUD; there are no DEA patient‑limit caps.

    Documentation Required

    Maintain current DEA registration with Schedule III authority

    Background

    The DEA eliminated the DATA‑Waiver (X‑Waiver) program effective January 12, 2023. As a result, waiver (X‑Waiver) registration numbers are no longer required for buprenorphine prescriptions and will not be accepted. Any practitioner with a current DEA registration that includes Schedule III authority may prescribe buprenorphine for opioid use disorder, and there are no limits on the number of patients a prescriber may treat with buprenorphine under this change. Additionally, the DEA announced new training requirements effective June 21, 2023: prescribers applying for or renewing DEA registration must complete an 8-hour training on identifying and treating addiction.

    Definitions

    inv-11: DATA-Waiver (X-Waiver) definition
    DefinitionDATA-Waiver (X-Waiver): previously required special registration number enabling certain practitioners to prescribe buprenorphine for opioid use disorder; no longer required.
    Current statusWaiver applications are no longer accepted; DATA-Waiver/X-Waiver numbers are not needed for any buprenorphine prescription.
    Prescribing authority now requiredStandard DEA registration that includes Schedule III authority suffices to prescribe buprenorphine for OUD.
    Patient limitsThere are no longer any limits on the number of patients a prescriber may treat for OUD with buprenorphine.

    Level of Care Criteria

    Treatment Modalities

    Medication for OUD (Buprenorphine)

    Buprenorphine prescribing: Prescriber holds current DEA registration with Schedule III authority; DATA-Waiver not required

    Applicable to treatment of OUD

    Revision History

    2023-01-12Regulatory change

    DEA confirmed elimination of the DATA‑Waiver (X‑Waiver) program and stated waiver applications will no longer be accepted; DATA‑Waiver numbers are no longer needed for buprenorphine prescriptions.

    2023-01-12Coverage policy revision

    San Francisco Health Plan updated prescribing requirements to allow any practitioner with a current DEA registration that includes Schedule III authority to prescribe buprenorphine for opioid use disorder and removed previous patient limits.

    2023-06-21Training requirement effective date
    Policy Summary
    Payersanfranciscohealthplan
    PolicyBuprenorphine prescribing after DATA-Waiver removal
    Policy CodePolicy N/A
    Change TypeOperational — removal of DATA-WaiverDEA training added
    Effective DateJan 12, 2023
    Next Review DateN/A
    Key ActionEnsure prescriber has and maintains a current DEA registration that includes Schedule III authority before prescribing buprenorphine.
    SourceLink
    On This Page
    Coverage Criteria for Buprenorphine PrescribingCoding and Administrative DetailsProvider Actions, Documentation, and RiskBackgroundDefinitionsLevel of Care CriteriaTreatment ModalitiesRevision History

    Prescribers must have and maintain a current DEA registration that includes Schedule III authority to prescribe buprenorphine for opioid use disorder.

    Denial Risk

    Risk of denial without Schedule III DEA registration

    Prescriptions may be denied if the prescriber does not have a valid DEA registration that includes Schedule III authority when prescribing buprenorphine for OUD.

    Latest

    New DEA requirement effective June 21, 2023: prescribers applying for or renewing DEA registration must complete an eight‑hour training on identifying and treating addiction.